Seclidemstat Access for Sarcoma

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Salarius Pharmaceuticals, LLC

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial allows patients who have previously benefited from seclidemstat to continue their treatment. Seclidemstat is a drug that aims to stop cancer cells from growing by blocking essential proteins. The trial targets patients who are still seeing positive results.

Eligibility Criteria

This trial is for patients who have been part of previous Salarius studies and are still benefiting from Seclidemstat, either alone or with other treatments. They must follow the study rules, use contraception if they can have children, and not be pregnant or breastfeeding. People can't join if they were taken off the original study treatment for any reason except to join this new one.

Inclusion Criteria

I am currently in a Salarius study and taking seclidemstat, with no more than a 14-day break between studies.

I am responding well to my current seclidemstat treatment.

I agree to use birth control during the study and will report any pregnancy immediately.

Exclusion Criteria

Pregnant and breastfeeding women

Patient permanently discontinued from parent study treatment for any reason other than entering this rollover study

Receiving prohibited concomitant therapy as described in the rollover protocol or therapy not allowed in the parent protocol

Treatment Details

Interventions

• Seclidemstat (LSD1 Inhibitor)

Trial Overview The trial provides ongoing access to Seclidemstat (SP-2577) for those already seeing positive effects from it in past trials by Salarius. It's a rollover protocol which means patients continue with the same medication without interruption.

Participant Groups

Group I: TC Combination Experimental Treatment 1 Intervention

Combination of seclidemstat with topotecan and cyclophosphamide, as assigned per parent protocol

Group II: Single agent Experimental Treatment 1 Intervention

Single agent seclidemstat, as assigned per parent protocol

Who Is Running the Clinical Trial?

Salarius Pharmaceuticals, LLC

Lead Sponsor

Trials

5

Recruited

160+